Company
Exelixis INC
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
2
2 still marketed
Novel approvals
1
Approvals since 2021
5
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Cabometyx new use OrphanSep 10, 2025
- Cabometyx new use OrphanMar 26, 2025
- Cabometyx new use Jul 14, 2022
- Cabometyx new use Breakthrough therapyPriority reviewOrphanSep 17, 2021
- Cabometyx new use Priority reviewJan 22, 2021
- Cabometyx new use OrphanJan 14, 2019
- Cabometyx new use Priority reviewDec 19, 2017
- Cometriq new use May 20, 2016
- Cabometyx approved Breakthrough therapyPriority reviewOrphanApr 25, 2016
- Cometriq approved NovelPriority reviewOrphanNov 29, 2012
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (2)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.